Statins And Stroke

被引:14
作者
Bersano, A. [1 ]
Ballabio, E. [1 ]
Lanfranconi, S. [1 ]
Mazzucco, S. [2 ]
Candelise, L. [1 ]
Monaco, S. [2 ]
机构
[1] Osped Maggiore, Policlin Mangiagalli & Regina Elena, IRCCS Fdn, I-20122 Milan, Italy
[2] Univ Verona, Dept Neurol & Visual Sci, I-37100 Verona, Italy
关键词
Statins; stroke; primary prevention; secondary prevention; brain haemorrhage; adverse effects;
D O I
10.2174/092986708785909139
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Pharmacological studies highlighted pleiotropic effects of statins, that seem to influence atherogenesis not only by increasing atherosclerotic plaque stability but also by modulating endothelial function and inflammation and acting on platelet aggregation and thrombosis. Despite a strong association between increased levels of low-density lipoprotein cholesterol (LDL-C) and the incidence of coronary heart disease (CHD) has been well proven, it not yet established whether serum LDL-C levels are related to stroke incidence. The major aim of this paper is to perform a comprehensive up-to-date review of research papers, meta-analyses and randomized controlled clinical trials reporting the effects of statins in primary and secondary stroke prevention strategies. In addition, our work provides an overview on statin chemical structure, mechanism of action and pharmacological properties, investigating also most common adverse effects and relationship between statin therapy and haemorrhagic stroke risk, in order to assess drugs safety. Although studies are heterogeneous, our analysis shows that statins reduce the risk of stroke occurrence in high risk patients and seem also to reduce stroke recurrence. Moreover, the low incidence and reversibility of adverse effects, and the unclear association with hemorrhagic events, support the safe use of these drugs.
引用
收藏
页码:2380 / 2392
页数:13
相关论文
共 128 条
[1]
LOVASTATIN - WARFARIN INTERACTION [J].
AHMAD, S .
ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (11) :2407-2407
[2]
Effect of statins in stroke prevention [J].
Amarenco, P .
CURRENT OPINION IN LIPIDOLOGY, 2005, 16 (06) :614-618
[3]
Statins in stroke prevention and carotid atherosclerosis -: Systematic review and up-to-date meta-analysis [J].
Amarenco, P ;
Labreuche, J ;
Lavallée, P ;
Touboul, PJ .
STROKE, 2004, 35 (12) :2902-2909
[4]
Amarenco P, 2006, NEW ENGL J MED, V355, P549
[5]
Oral anticoagulant drug interactions with statins: Case report of fluvastatin and review of the literature [J].
Andrus, MR .
PHARMACOTHERAPY, 2004, 24 (02) :285-290
[6]
The safety of statins in clinical practice [J].
Armitage, Jane .
LANCET, 2007, 370 (9601) :1781-1790
[7]
Clinical practice: Low HDL cholesterol levels [J].
Ashen, MD ;
Blumenthal, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (12) :1252-1260
[8]
Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study [J].
Athyros, VG ;
Mikhailidis, DP ;
Papageorgiou, AA ;
Mercouris, BR ;
Athyrou, VV ;
Symeonidis, AN ;
Basayannis, EO ;
Demitriadis, DS ;
Kontopoulos, AG .
CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (08) :499-502
[9]
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[10]
Rosuvastatin-warfarin drug interaction [J].
Barry, M .
LANCET, 2004, 363 (9405) :328-328